IL-12/IL-23p40 identified as a downstream target of apremilast in models of arthritis
Background: Apremilast (Otezla ® ) is a phosphodiesterase 4 (PDE4) inhibitor approved for the treatment of psoriasis and psoriatic arthritis (PsA), but the reason why apremilast shows clinical effect is not fully understood. The objective of this study was to study the downstream effects of apremila...
Main Authors: | Tue W. Kragstrup, Mary Adams, Søren Lomholt, Morten A. Nielsen, Line D. Heftdal, Peter Schafer, Bent Deleuran |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2019-02-01
|
Series: | Therapeutic Advances in Musculoskeletal Disease |
Online Access: | https://doi.org/10.1177/1759720X19828669 |
Similar Items
-
The IL-20 Cytokine Family in Rheumatoid Arthritis and Spondyloarthritis
by: Tue W. Kragstrup, et al.
Published: (2018-09-01) -
Responses to Cytokine Inhibitors Associated with Cellular Composition in Models of Immune‐Mediated Inflammatory Arthritis
by: Morten A. Nielsen, et al.
Published: (2020-01-01) -
Clinical experience with apremilast for psoriatic arthritis
by: E. Yu. Loginova, et al.
Published: (2018-09-01) -
The effect of Apremilast on signal transduction and IL-10 production in CD39high regulatory B cells in patients with psoriatic arthritis
by: Lazaros I. Sakkas, et al.
Published: (2018-01-01) -
Clinical potential of apremilast in the treatment of psoriatic arthritis
by: Cauli A, et al.
Published: (2014-06-01)